1. Glucagon-like peptide 1 receptor agonist: A potential game changer for cholangiocarcinoma.
- Author
-
Trakoonsenathong R, Chiu CF, and Saengboonmee C
- Subjects
- Animals, Humans, Cell Proliferation drug effects, Dipeptidyl-Peptidase IV Inhibitors administration & dosage, Dipeptidyl-Peptidase IV Inhibitors adverse effects, Bile Duct Neoplasms chemically induced, Bile Duct Neoplasms epidemiology, Bile Duct Neoplasms pathology, Cholangiocarcinoma chemically induced, Cholangiocarcinoma epidemiology, Cholangiocarcinoma pathology, Glucagon-Like Peptide-1 Receptor Agonists administration & dosage, Glucagon-Like Peptide-1 Receptor Agonists adverse effects
- Abstract
Glucagon-like peptide-1 receptor (GLP-1R) agonist, a subgroup of incretin-based anti-diabetic therapies, is an emerging medication with benefits in reducing blood glucose and weight and increasing cardiovascular protection. Contrarily, concerns have been raised about GLP-1R agonists increasing the risk of particular cancers. Recently, several epidemiological studies reported contradictory findings of incretin-based therapy on the risk modification for cholangiocarcinoma (CCA). The first cohort study demonstrated that incretin-based therapy was associated with an increased risk of CCA. Later studies, however, showed a null effect of incretin-based therapy on CCA risk for dipeptidyl peptidase-4 inhibitor nor GLP-1R agonist. Mechanistically, glucagon-like peptide 1 receptor is multifunctional, including promoting cell growth. High GLP-1R expressions were associated with progressive phenotypes of CCA cells in vitro . Unexpectedly, the GLP-1R agonist showed anti-tumor effects on CCA cells in vitro and in vivo with unclear mechanisms. Our recent report also showed that GLP-1R agonists suppressed the expression of GLP-1R in CCA cells in vitro and in vivo , leading to the inhibition of CCA tumor growth. This editorial reviews recent evidence, discusses the potential effects of GLP-1R agonists in CCA patients, and proposes underlying mechanisms that would benefit from further basic and clinical investigation., Competing Interests: Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article., (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF